Affymetrix Introduces Axiom® miRNA Target Site Genotyping Arrays
November 06 2012 - 7:00AM
Business Wire
Affymetrix, Inc. (NASDAQ:AFFX) introduces Axiom® miRNA
Target Site Genotyping Arrays, the only high-density genotyping
tools for genome-wide evaluation of microRNA (miRNA) target sites.
These new arrays will enable comprehensive studies to elucidate how
genomic variation in miRNA regulatory machinery influences gene
expression and disease risk. It interrogates 238,000 SNPs and
indels in genes for all parts of the miRNA cascade including
miRNAs, their mRNA target sites, and silencing machinery.
Last month the Encyclopedia of DNA Elements (ENCODE) Consortium,
an international collaboration of research groups funded by the
National Human Genome Research Institute, reported exciting data
upending the view that large portions of the human genome contain
“junk” DNA. This non-coding genetic content has been shown to play
a larger role in complex diseases than previously thought. “We now
realize that a portion of this non-coding DNA is highly relevant in
the regulation of translation and plays a role in health and
disease,” stated Andy Last, PhD, Executive Vice President of
Genetic Analysis and Clinical Applications Business Unit at
Affymetrix. “These new arrays are powerful tools for performing
large scale genomic analysis of these important regulatory miRNA
elements potentially involved in complex disease.”
These genotyping arrays will complement Affymetrix’ suite of
miRNA expression analysis products, including GeneChip® miRNA 3.0
Array, QuantiGene® 2.0 miRNA Assay, and QuantiGene® ViewRNA in situ
Hybridization (ISH) Cell Assay, which enable comprehensive and
integrated analysis to advance our understanding of the role of
gene regulation in health and disease. Over 80 percent of the
content on the new Axiom® miRNA Target Site Genotyping Arrays is
not found on other widely used genotyping arrays and will enable
scientists to survey their sample cohorts against important new
content and supplement their existing association studies via
meta-analysis.
“The studies we are performing using the Axiom® miRNA Target
Site Genotyping Array are showing promising results,” stated
Professor Stephen B. Gruber, M.D., Ph.D., M.P.H., Director of the
USC Norris Comprehensive Cancer Center, Keck School of Medicine of
the University of Southern California. “We believe this array,
focused on detecting variation in miRNA regulatory machinery,
represents a new opportunity to broadly interrogate an important
class of variants relevant to cancer research.”
In addition to the predesigned catalog version, customers can
easily choose to add their own content to Axiom® miRNA Target Site
Genotyping Arrays, including variants in long non-coding RNAs for
disease association studies.
Preliminary studies with the new array will be presented at the
2012 annual meeting of the American Society of Human Genetics
(ASHG) in San Francisco at 10:40 a.m. on November 10, 2012. The
talk, entitled “Case-control study of microRNA target site
polymorphisms and colorectal cancer in the Ashkenazi Jewish
population” will be presented by Dr. Michael Shapero, Sr. Director
of Molecular Genetics, Affymetrix.
Axiom® miRNA Target Site Genotyping Arrays are available now and
custom versions of the array can be delivered in 4-6 weeks.
Products mentioned in this release are for research use only.
Not for diagnostic procedures.
PLEASE NOTE: Affymetrix®, the Affymetrix logo, Axiom®,
GeneChip®, QuantiGene®, and all other trademarks are the property
of Affymetrix, Inc. All other trademarks are the property of their
respective owners.
About Affymetrix
Affymetrix technologies are used by the world's top
pharmaceutical, diagnostic, and biotechnology companies as well as
leading academic, government, and nonprofit research institutes.
More than 26,000 peer-reviewed papers have been published citing
the technologies. Affymetrix is headquartered in Santa Clara,
Calif., and has manufacturing facilities in Santa Clara, San Diego,
Cleveland, Ohio, Singapore, and Austria. The company has about
1,180 employees worldwide and maintains sales and distribution
operations across Europe, Asia, and Latin America. For more
information about Affymetrix, please visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2011, and other SEC reports for subsequent
quarterly periods.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024